Related Experiment Video

Updated: May 22, 2026

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

A novel bitriazolyl acyclonucleoside endowed with dual antiproliferative and immunomodulatory activity

Yi Xia1, Menghua Wang, Olivier Demaria

  • 1Département de Chimie, CINaM CNRS UMR 7325, Aix-Marseille Université, Marseille, France.

Journal of Medicinal Chemistry
|May 15, 2012
PubMed

Insights

A novel compound shows potent anticancer effects by inducing apoptosis and enhances immune response via Toll-like receptor 7 (TLR7) signaling. This dual-action drug candidate offers a promising new approach for cancer therapy.

Area of Science:

  • Medicinal Chemistry
  • Immunology
  • Cancer Biology

Background:

  • Novel drug discovery for cancer therapy is crucial.
  • Developing agents with dual anticancer and immunomodulatory properties is a key goal.

Purpose of the Study:

  • To discover and characterize a novel bitriazolyl acyclonucleoside.
  • To evaluate its antiproliferative effects on cancer cell lines.
  • To investigate its immunomodulatory activity in dendritic cells.

Main Methods:

  • Synthesis of a novel bitriazolyl acyclonucleoside.
  • In vitro antiproliferative assays against various cancer cell lines.
  • Assessment of immune stimulation in dendritic cells via Toll-like receptor 7 (TLR7) signaling.

Main Results:

  • The compound demonstrated potent antiproliferative activity across multiple cancer cell lines.
  • The mechanism of action involves caspase-dependent apoptosis.
  • Significant immune response stimulation was observed in dendritic cells through TLR7 activation.

Conclusions:

  • The novel bitriazolyl acyclonucleoside possesses significant dual anticancer and immunomodulatory potential.
  • This compound represents a promising new drug candidate for advanced cancer therapy.
  • Further research into its therapeutic applications is warranted.

More Related Videos

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation07:20

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation

Published on: January 14, 2011

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Inhibitors of Bacterial DNA Synthesis01:28

Inhibitors of Bacterial DNA Synthesis

Bacterial pathogens depend on precise and efficient DNA replication to sustain infection. Two type II topoisomerases—DNA gyrase and topoisomerase IV—are critical to this process, as they resolve DNA supercoiling and unlink chromosomes during replication. Fluoroquinolones, synthetic derivatives of quinolones, exploit this mechanism by stabilizing the transient DNA–enzyme cleavage complex, preventing strand religation, and causing lethal double-strand breaks. These antibiotics are selectively...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...